Limited miR-17-92 overexpression drives hematologic malignancies

Leukemia Research

Volumn 39, Issue 3, 2015, Pages 335-341

  Danielson, Laura S ^a,c   Reavie, Linsey ^a,d   Coussens, Marc ^a   Davalos, Veronica ^a   Castillo Martin, Mireia ^b   Guijarro, Maria V ^a,e   Coffre, Maryaline ^a   Cordon Cardo, Carlos ^b   Aifantis, Iannis ^a   Ibrahim, Sherif ^a   Liu, Cynthia ^a   Koralov, Sergei B ^a   Hernando, Eva ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

Lymphoma; MiR 17 92; Mouse model

Indexed keywords

CD45 ANTIGEN; COMPLEMENTARY DNA; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; MICRORNA; MICRORNA 17 92; TRANSGELIN; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CRE RECOMBINASE; INTEGRASE; MESSENGER RNA; MIRN17-92 MICRORNA, MOUSE; MUSCLE PROTEIN; TAGLN PROTEIN, MOUSE;

AGE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL LINEAGE; CONTROLLED STUDY; DOSE RESPONSE; GENE OVEREXPRESSION; GENETIC RECOMBINATION; HEART ARRHYTHMIA; HEART FUNCTION; HEART SIZE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HETEROZYGOSITY; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; HUMAN CELL; HYPERTROPHIC CARDIOMYOPATHY; LARGE CELL LYMPHOMA; LEUKEMOGENESIS; LIFESPAN; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MARGINAL ZONE LYMPHOMA; MICROSCOPY; MORPHOGENESIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SPLEEN CELL; SPLENOMEGALY; SURVIVAL RATE; T LYMPHOCYTE; VASCULAR SMOOTH MUSCLE; ANIMAL; CELL PROLIFERATION; CELL TRANSFORMATION; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; HEMATOLOGIC DISEASE; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; IMMUNOENZYME TECHNIQUES; INTEGRASES; MICE; MICROFILAMENT PROTEINS; MICRORNAS; MUSCLE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84924044294     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.12.002     Document Type: Article

References (33)

1. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
2. Winter J., Jung S., Keller S., Gregory R.I., Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009, 11:228-234.
3. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
4. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., et al. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
5. Ota A., Tagawa H., Karnan S., Tsuzuki S., Karpas A., Kira S., et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004, 64:3087-3095.
6. Mi S., Li Z., Chen P., He C., Cao D., Elkahloun A., et al. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci U S A 2010, 107:3710-3715.
7. Petrocca F., Visone R., Onelli M.R., Shah M.H., Nicoloso M.S., de Martino I., et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008, 13:272-286.
8. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261.
9. Osada H., Takahashi T. let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci 2011, 102:9-17.
10. Yu G., Tang J.Q., Tian M.L., Li H., Wang X., Wu T., et al. Prognostic values of the miR-17-92 cluster and its paralogs in colon cancer. J Surg Oncol 2012, 106:232-237.
11. Mendell J.T. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008, 133:217-222.
12. Olive V., Li Q., He L. mir-17-92: a polycistronic oncomir with pleiotropic functions. Immunol Rev 2013, 253:158-166.
13. Mogilyansky E., Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 2013, 20:1603-1614.
14. Lepore J.J., Cheng L., Min Lu M., Mericko P.A., Morrisey E.E., Parmacek M.S. High-efficiency somatic mutagenesis in smooth muscle cells and cardiac myocytes in SM22alpha-Cre transgenic mice. Genesis 2005, 41:179-184.
15. Holtwick R., Gotthardt M., Skryabin B., Steinmetz M., Potthast R., Zetsche B., et al. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci U S A 2002, 99:7142-7147.
16. Mao X., Fujiwara Y., Chapdelaine A., Yang H., Orkin S.H. Activation of EGFP expression by Cre-mediated excision in a new ROSA26 reporter mouse strain. Blood 2001, 97:324-326.
17. Xiao C., Srinivasan L., Calado D.P., Patterson H.C., Zhang B., Wang J., et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008, 9:405-414.
18. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues; Press I 2008, IARC Press.
19. Koralov S.B., Novobrantseva T.I., Konigsmann J., Ehlich A., Rajewsky K. Antibody repertoires generated by VH replacement and direct VH to JH joining. Immunity 2006, 25:43-53.
20. Ehlich A., Martin V., Muller W., Rajewsky K. Analysis of the B-cell progenitor compartment at the level of single cells. Curr Biol 1994, 4:573-583.
21. Danielson L.S., Menendez S., Attolini C.S., Guijarro M.V., Bisogna M., Wei J., et al. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. Am J Pathol 2010, 177:908-917.
22. Wilson K.D., Hu S., Venkatasubrahmanyam S., Fu J.D., Sun N., Abilez O.J., et al. Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499. Circ Cardiovasc Genet 2010, 3:426-435.
23. Danielson L.S., Park D.S., Rotllan N., Chamorro-Jorganes A., Guijarro M.V., Fernandez-Hernando C., et al. Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis. FASEB J 2013, 27:1460-1467.
24. Zinzani P.L. The many faces of marginal zone lymphoma. Hematol Am Soc Hematol Educ Program 2012, 2012:426-432.
25. Fu K., Mende Y., Bhetwal B.P., Baker S., Perrino B.A., Wirth B., et al. Tra2beta protein is required for tissue-specific splicing of a smooth muscle myosin phosphatase targeting subunit alternative exon. J Biol Chem 2012, 287:16575-16585.
26. Cohen E.D., Ihida-Stansbury K., Lu M.M., Panettieri R.A., Jones P.L., Morrisey E.E. Wnt signaling regulates smooth muscle precursor development in the mouse lung via a tenascin C/PDGFR pathway. J Clin Invest 2009, 119:2538-2549.
27. Lepore J.J., Mericko P.A., Cheng L., Lu M.M., Morrisey E.E., Parmacek M.S. GATA-6 regulates semaphorin 3C and is required in cardiac neural crest for cardiovascular morphogenesis. J Clin Invest 2006, 116:929-939.
28. High F.A., Zhang M., Proweller A., Tu L., Parmacek M.S., Pear W.S., et al. An essential role for Notch in neural crest during cardiovascular development and smooth muscle differentiation. J Clin Invest 2007, 117:353-363.
29. Naik V., Leaf E.M., Hu J.H., Yang H.Y., Nguyen N.B., Giachelli C.M., et al. Sources of cells that contribute to atherosclerotic intimal calcification: an in vivo genetic fate mapping study. Cardiovasc Res 2012, 94:545-554.
30. Shen Z., Li C., Frieler R.A., Gerasimova A.S., Lee S.J., Wu J., et al. Smooth muscle protein 22 alpha-Cre is expressed in myeloid cells in mice. Biochem Biophys Res Commun 2012, 422:639-642.
31. Jin H.Y., Oda H., Lai M., Skalsky R.L., Bethel K., Shepherd J., et al. MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J 2013, 32:2377-2391.
32. Sandhu S.K., Fassan M., Volinia S., Lovat F., Balatti V., Pekarsky Y., et al. B-cell malignancies in microRNA Emu-miR-17~92 transgenic mice. Proc Natl Acad Sci U S A 2013, 110:18208-18213.
33. Olive V., Bennett M.J., Walker J.C., Ma C., Jiang I., Cordon-Cardo C., et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009, 23:2839-2849.